{"protocolSection":{"identificationModule":{"nctId":"NCT00129805","orgStudyIdInfo":{"id":"MCI9042-15"},"organization":{"fullName":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"},"briefTitle":"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)","officialTitle":"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial"},"statusModule":{"statusVerifiedDate":"2008-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2001-01"},"primaryCompletionDateStruct":{"date":"2004-09","type":"ACTUAL"},"completionDateStruct":{"date":"2004-09","type":"ACTUAL"},"studyFirstSubmitDate":"2005-08-11","studyFirstSubmitQcDate":"2005-08-11","studyFirstPostDateStruct":{"date":"2005-08-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2008-08-18","lastUpdatePostDateStruct":{"date":"2008-08-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"General Manager, Clinical Research Department I","oldOrganization":"Mitsubishi Tanabe Pharma Corporation"},"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.\n\nS-ACCESS was a randomized, double-blinded trial to compare the relative efficacy of sarpogrelate (100mg three times daily) and aspirin (81mg once daily) in 1510 patients with recent cerebral infarction. Patients were followed for 0.9 to 3.5 years. The primary endpoint was recurrence of cerebral infarction; relative safety was also assessed."},"conditionsModule":{"conditions":["Cerebral Infarction"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1510,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MCI-9042","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-9042"]},{"label":"Aspirin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aspirin"]}],"interventions":[{"type":"DRUG","name":"MCI-9042","armGroupLabels":["MCI-9042"],"otherNames":["Sarpogrelate(INN)","ANPLAG(R)"]},{"type":"DRUG","name":"Aspirin","armGroupLabels":["Aspirin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"recurrence of cerebral infarction"}],"secondaryOutcomes":[{"measure":"intracerebral hemorrhage, subarachnoid hemorrhage, undetermined stroke, transient ischemic attack, myocardial infarction, unstable angina, or vascular death"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cerebral infarction except cardiac source of embolism\n* Onset ≧ 1 week to ≦ 6 months before randomization\n* Neurological signs persisting ≧ 1 day from onset\n* Computed tomography (CT) or magnetic resonance imaging (MRI) detection of responsible site\n* Age ≧ 20 years\n* Systolic pressure ≦ 180 mmHg; diastolic pressure ≦ 110 mmHg\n\nExclusion Criteria:\n\n* Functional outcome at randomization: Modified Rankin Scale = 4, 5\n* Previous or planned vascular surgery for cerebral infarction\n* History of intracranial hemorrhage\n* History of systemic bleeding, or other history of bleeding diathesis or coagulopathy\n* Severe complications (renal or hepatic insufficiency, heart failure, hemopathy, etc.)\n* Pregnant or possibly pregnant women, or nursing mothers\n* History of sarpogrelate and aspirin sensitivity\n* Treating malignant tumor or treated within 5 years\n* Current peptic ulceration","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yukito Shinohara, MD","affiliation":"Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital","role":"STUDY_CHAIR"}]},"referencesModule":{"references":[{"pmid":"18388340","type":"RESULT","citation":"Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F; S-ACCESS Study Group. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008 Jun;39(6):1827-33. doi: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"C000064294","term":"Sarpogrelate"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000012702","term":"Serotonin Antagonists"},{"id":"D000018490","term":"Serotonin Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M209308","name":"Sarpogrelate","asFound":"Transitional Cell Carcinoma","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M15202","name":"Serotonin","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}